The odds for clinical remission achievement in patients with type 2 inflammatory severe asthma were greater with dupilumab vs ...

Sixteen weeks of dupilumab improved lesion severity scores 59.8% vs 15.2% with placebo in 94 adults with moderate-to-severe ...

The FDA approved Dupixent (dupilumab) as a treatment for moderate-to-severe atopic dermatitis for adolescents in 2019, then for older children, ages 6 to 11, a year later, and, two years later, for ...

Dupilumab improved lung function and reduced severe respiratory exacerbations in patients with asthma and APBA. Learn more.

This academic literature is a systematic review that examined the efficacy of biologics for patients with moderate to very ...

In all seasons, adults with COPD and type 2 inflammation had a decreased annualized rate of moderate/severe exacerbations with dupilumab vs. placebo, according to data presented at the European ...

Dupilumab was more effective than other biologics in achieving clinical remission in adults and adolescents with several types of severe asthma, based on data presented at the European Respiratory ...

For patients with severe CRSwNP and concomitant eosinophilic otitis media, dupilumab treatment may provide meaningful benefits over a 12-month period.

Delaying dupilumab initiation beyond 90 days after a severe asthma exacerbation was linked to a 32% increase in predicted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that treatment with dupilumab significantly restores skin barrier function and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...